NanoViricides Inc. (NNVC)

[Rawnoc]

Ansun BioPharma Announces Breakthrough Designation for its Experimental Drug DAS181

https://www.prnewswire.com/news-releases/ansun-biopharma-announces-breakthrough-designation-for-its-experimental-drug-das181-300533677.html?tc=

"Ansun recently completed a Phase 2 study of DAS181 for treatment of PIV infection in hospitalized, immunocompromised patients and is now in the planning stage of a Phase 3 study. In addition, Ansun has worked in collaboration with the FDA to make DAS181 available for treatment of over 130 pediatric and adult patients through compassionate use under single patient emergency IND applications. "We are excited about this designation and look forward to continuing to work closely with the Division of Antiviral products at the FDA as we plan and implement a Phase 3 study for this severely ill patient population," said Dr. George Wang, Chief Technical Officer of Ansun Biopharma."